VEGF164 isoform specific regulation of T-cell-dependent experimental colitis in mice

Inflammatory Bowel Diseases

Volumn 17, Issue 7, 2011, Pages 1501-1512

  Chidlow Jr , John H ^a,b   Glawe, John D ^a   Pattillo, Christopher B ^a   Pardue, Sibile ^a   Zhang, Songlin ^a   Kevil, Christopher G ^a,b  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

angiogenesis; colitis; IBD; inflammation; T cell; VEGF

Indexed keywords

APTAMER; CD4 ANTIGEN; CD45RB ANTIGEN; ISOPROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 164; VASCULOTROPIN A; CD45 ANTIGEN; HOMEODOMAIN PROTEIN; RAG 1 PROTEIN; RAG-1 PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; ENTERITIS; EXPERIMENTAL MODEL; HISTOPATHOLOGY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; T LYMPHOCYTE; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; CD4+ T LYMPHOCYTE; COLON; DISEASE MODEL; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; REGULATORY T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD45; APTAMERS, NUCLEOTIDE; CD4-POSITIVE T-LYMPHOCYTES; COLITIS; COLON; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HOMEODOMAIN PROTEINS; HUMANS; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ISOFORMS; T-LYMPHOCYTES, REGULATORY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79958783427     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21525     Document Type: Article

References (41)

1. Warren S, Sommers SC., Pathology of regional ileitis and ulcerative colitis. JAMA. 1954; 154: 189-193.
2. Reifferscheid M, Wolfram E,. [Resection or by-pass anastomosis in regional enteritis?] Chirurg. 1962; 33: 164-172.
3. Bacaner MB., Quantitative measurement of regional colon blood flow in the normal and pathological human bowel. Gastroenterology. 1966; 51: 764-777.
4. Knutson H, Lunderquist A, Lunderquist A., Vascular changes in Crohn's disease. Am J Roentgenol Radium Ther Nucl Med. 1968; 103: 380-385.
5. Chidlow JH Jr, Langston W, Greer JJ, et al. Differential angiogenic regulation of experimental colitis. Am J Pathol. 2006; 169: 2014-2030. (Pubitemid 351181962)
6. Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006; 130: 2060-2073. (Pubitemid 43816964)
7. Brahme F, Lindstrom C., A comparative radiographic and pathological study of intestinal vaso-architecture in Crohn's disease and in ulcerative colitis. Gut. 1970; 11: 928-940.
8. Hatoum OA, Heidemann J, Binion DG., The intestinal microvasculature as a therapeutic target in inflammatory bowel disease. Ann N Y Acad Sci. 2006; 1072: 78-97. (Pubitemid 44448445)
9. Laroux FS, Grisham MB., Immunological basis of inflammatory bowel disease: role of the microcirculation. Microcirculation. 2001; 8: 283-301. (Pubitemid 33598134)
10. Fishman SJ, Feins NR, Folkman J,. Long-term remission of Crohn's disease treated with thalidomide: a seminal case report. Angiogenesis. 1999; 3: 201-204. (Pubitemid 129644148)
11. Bariol C, Meagher AP, Vickers CR, et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol. 2002; 17: 135-139. (Pubitemid 34415665)
12. Beck PL, Podolsky DK., Growth factors in inflammatory bowel disease. Inflamm Bowel Dis. 1999; 5: 44-60.
13. Kanazawa S, Tsunoda T, Onuma E, et al. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol. 2001; 96: 822-828. (Pubitemid 32240738)
14. Kapsoritakis A, Sfiridaki A, Maltezos E, et al. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis. 2003; 18: 418-422. (Pubitemid 37062733)
15. Sunderkotter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukoc Biol. 1994; 55: 410-422. (Pubitemid 24097250)
16. Griga T, Werner S, Koller M, et al. Vascular endothelial growth factor (VEGF) in Crohn's disease: increased production by peripheral blood mononuclear cells and decreased VEGF165 labeling of peripheral CD14+ monocytes. Dig Dis Sci. 1999; 44: 1196-1201. (Pubitemid 29297228)
17. Ferrara N, Gerber HP, LeCouter J., The biology of VEGF and its receptors. Nat Med. 2003; 9: 669-676. (Pubitemid 36749215)
18. Kusumanto YH, Dam WA, Hospers GA, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003; 6: 283-287. (Pubitemid 38987537)
19. Ng YS, Rohan R, Sunday ME, et al. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn. 2001; 220: 112-121. (Pubitemid 32107812)
20. Breier G, Albrecht U, Sterrer S, et al. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development. 1992; 114: 521-532.
21. Maharaj AS, Saint-Geniez M, Maldonado AE, et al. Vascular endothelial growth factor localization in the adult. Am J Pathol. 2006; 168: 639-648. (Pubitemid 43271161)
22. Ferrara N., Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004; 25: 581-611. (Pubitemid 39099316)
23. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3: 391-400. (Pubitemid 38618122)
24. Fukasawa M, Korc M., Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res. 2004; 10: 3327-3332. (Pubitemid 38685437)
25. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001; 19: 843-850. (Pubitemid 32119100)
26. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351: 2805-2816. (Pubitemid 40051904)
27. Lee JH, Canny MD, De Erkenez A, et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci U S A. 2005; 102: 18902-18907. (Pubitemid 43049539)
28. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997; 57: 4593-4599. (Pubitemid 27441066)
29. Chidlow JH Jr, Shukla D, Grisham MB, et al. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol. 2007; 293: G5-G18. (Pubitemid 47105158)
30. Langston W, Chidlow JH Jr, Booth BA, et al. Regulation of endothelial glutathione by ICAM-1 governs VEGF-A-mediated eNOS activity and angiogenesis. Free Radic Biol Med. 2007; 42: 720-729. (Pubitemid 46205151)
31. Chidlow JH Jr, Greer JJ, Anthoni C, et al. Endothelial caveolin-1 regulates pathologic angiogenesis in a mouse model of colitis. Gastroenterology. 2009; 136: 575-584 e2.
32. Tsiolakidou G, Koutroubakis IE, Tzardi M, et al. Increased expression of VEGF and CD146 in patients with inflammatory bowel disease. Dig Liver Dis. 2008; 40: 673-679.
33. Goebel S, Huang M, Davis WC, et al. VEGF-A stimulation of leukocyte adhesion to colonic microvascular endothelium: implications for inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2006; 290: G648-654.
34. Usui T, Ishida S, Yamashiro K, et al. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci. 2004; 45: 368-374. (Pubitemid 38140491)
35. Mor F, Quintana FJ, Cohen IR., Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol. 2004; 172: 4618-4623. (Pubitemid 38375280)
36. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology. 2009; 136: 585-595 e5.
37. Sandor Z, Deng XM, Khomenko T, et al. Altered angiogenic balance in ulcerative colitis: a key to impaired healing ? Biochem Biophys Res Commun. 2006; 350: 147-150. (Pubitemid 44466584)
38. Jones MK, Tomikawa M, Mohajer B, et al. Gastrointestinal mucosal regeneration: role of growth factors. Front Biosci. 1999; 4: D303-309.
39. Hindryckx P, Waeytens A, Laukens D, et al. Absence of placental growth factor blocks dextran sodium sulfate-induced colonic mucosal angiogenesis, increases mucosal hypoxia and aggrevates acute colonic injury. Lab Invest. 2010; 90: 566-576.
40. Chen HX, Cleck JN., Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009; 6: 465-477.
41. Tunon J, Ruiz-Moreno JM, Martin-Ventura JL, et al. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. Surv Ophthalmol. 2009; 54: 339-348.